Opinion

Video

Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Marwan Fakih, MD

Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.

Video content above is prompted by the following:

How do these new therapy options (FTD/TPI plus bevacizumab, fruquintinib) compare with regorafenib in terms of efficacy and safety?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Elise Tremblay
Related Content
AJMC
August 15th 2025

Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

Mario Enrico Canonico, MD, PhD Judith Hsia, MD Shih-Ting Chiu, PhD Pu-Kai Tseng James O. Mudd, MD Joshua D. Remick, MD Bansi Patel, MS Ya-Hsiu Chuang, PhD Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Marc P. Bonaca, MD, MPH
managed care cast logo
August 15th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM
AJMC
August 15th 2025

Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients

Pierantonio Russo, MD Henriette Coetzer, MD Erik M. Hendrickson, PhD Kenneth Boyle, DC Brent Wright, DrPH
managed care cast logo
August 15th 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
AJMC
August 15th 2025

Care Quality Metrics in Medicare During COVID-19 Pandemic

Jeanette Thornton, MPA Mark Hamelburg, JD Lynn Nonnemaker, PhD Sherzod Abdukadirov, PhD German Veselovskiy, MPP Sari Siegel, PhD
Biosimilars. | Image Credit: Shutter2U - stock.adobe.com
August 15th 2025

Switching Biologics in Psoriasis Boosts Effectiveness but Raises Infection Risk

Pearl Steinzor

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo